Status:
COMPLETED
Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke
Lead Sponsor:
Shanghai 6th People's Hospital
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
42-76 years
Brief Summary
Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible factor (HIF)...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute ischemic stroke
- Admission within 12 hours
Exclusion
- Lacunar infarction
- Cerebral hemorrhagic infarction
- Epilepsy or epileptic persons
- History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
- Contraindications to antiplatelet treatments
- Serial blood samples could not be obtained
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02297984
Start Date
October 1 2013
End Date
October 1 2014
Last Update
August 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Sixth People's Hospital
Shanghai, China, 200233